Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florine Obrist

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Molecular & Cellular Oncology|December 8, 2018
Cisplatin resistance coupled to enhanced sensitivity to metabolic interventionsMaria Castedo, Florine Obrist, Guido Kroemer
Molecular & Cellular Oncology|June 17, 2016
Trial watch - inhibiting PARP enzymes for anticancer therapyAntonella Sistigu, Gwenola Manic, Florine Obrist, et al.
Molecular & Cellular Oncology|June 17, 2016
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyGwenola Manic, Florine Obrist, Antonella Sistigu, et al.
Biochemical Pharmacology|September 10, 2014
PARP and other prospective targets for poisoning cancer cell metabolismJudith Michels, Florine Obrist, Maria Castedo, et al.
Molecular & Cellular Oncology|June 17, 2016
Chloroquine and hydroxychloroquine for cancer therapyGwenola Manic, Florine Obrist, Guido Kroemer, et al.
Molecular & Cellular Oncology|June 17, 2016
Trial Watch: Proteasomal inhibitors for anticancer therapyFlorine Obrist, Gwenola Manic, Guido Kroemer, et al.
Oncoimmunology|August 2, 2014
Trial watch: Immunostimulatory cytokines in cancer therapyErika Vacchelli, Fernando Aranda, Florine Obrist, et al.
Oncoimmunology|May 7, 2014
Trial Watch: DNA vaccines for cancer therapyJonathan Pol, Norma Bloy, Florine Obrist, et al.
Oncoimmunology|July 23, 2014
Trial Watch: Adoptive cell transfer for anticancer immunotherapyFernando Aranda, Erika Vacchelli, Florine Obrist, et al.
Biochemical Pharmacology|August 10, 2014
MCL-1 dependency of cisplatin-resistant cancer cellsJudith Michels, Florine Obrist, Ilio Vitale, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Molecular & Cellular Oncology|December 8, 2018
Cisplatin resistance coupled to enhanced sensitivity to metabolic interventionsMaria Castedo, Florine Obrist, Guido Kroemer
Molecular & Cellular Oncology|June 17, 2016
Trial watch - inhibiting PARP enzymes for anticancer therapyAntonella Sistigu, Gwenola Manic, Florine Obrist, et al.
Molecular & Cellular Oncology|June 17, 2016
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyGwenola Manic, Florine Obrist, Antonella Sistigu, et al.
Biochemical Pharmacology|September 10, 2014
PARP and other prospective targets for poisoning cancer cell metabolismJudith Michels, Florine Obrist, Maria Castedo, et al.
Molecular & Cellular Oncology|June 17, 2016
Chloroquine and hydroxychloroquine for cancer therapyGwenola Manic, Florine Obrist, Guido Kroemer, et al.
Molecular & Cellular Oncology|June 17, 2016
Trial Watch: Proteasomal inhibitors for anticancer therapyFlorine Obrist, Gwenola Manic, Guido Kroemer, et al.
Oncoimmunology|August 2, 2014
Trial watch: Immunostimulatory cytokines in cancer therapyErika Vacchelli, Fernando Aranda, Florine Obrist, et al.
Oncoimmunology|May 7, 2014
Trial Watch: DNA vaccines for cancer therapyJonathan Pol, Norma Bloy, Florine Obrist, et al.
Oncoimmunology|July 23, 2014
Trial Watch: Adoptive cell transfer for anticancer immunotherapyFernando Aranda, Erika Vacchelli, Florine Obrist, et al.
Biochemical Pharmacology|August 10, 2014
MCL-1 dependency of cisplatin-resistant cancer cellsJudith Michels, Florine Obrist, Ilio Vitale, et al.
Pageof 2